Targeting Histone Modifications in Bone and Lung Metastatic Cancers
Sign Up to like & getrecommendations! Published in 2021 at "Current Osteoporosis Reports"
DOI: 10.1007/s11914-021-00670-2
Abstract: Breast cancer frequently metastasizes to the bone and lung, but the ability to treat metastatic tumor cells remains a pressing clinical challenge. Histone deacetylases (HDACs) and histone acetyltransferases (HATs) have emerged as promising targets since… read more here.
Keywords: bone lung; hdac inhibitors; metastatic cancers; lung metastatic ... See more keywords
Peptide therapeutics in the management of metastatic cancers
Sign Up to like & getrecommendations! Published in 2022 at "RSC Advances"
DOI: 10.1039/d2ra02062a
Abstract: Cancer remains a leading health concern threatening lives of millions of patients worldwide. Peptide-based drugs provide a valuable alternative to chemotherapeutics as they are highly specific, cheap, less toxic and easier to synthesize compared to… read more here.
Keywords: peptide based; management metastatic; metastatic cancers; peptide therapeutics ... See more keywords
Burden of illness and research investments in translational sciences for pharmaceuticals in metastatic cancers.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of comparative effectiveness research"
DOI: 10.2217/cer-2016-0021
Abstract: AIM To explore whether investments in translational sciences for six metastatic cancers follow idiosyncratic returns to those investments rather than levels of burden of illness (BI). METHODS Associate the number of translational clinical trials in… read more here.
Keywords: research; translational sciences; metastatic cancers; investments translational ... See more keywords
Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review.
Sign Up to like & getrecommendations! Published in 2020 at "Neoplasma"
DOI: 10.4149/neo_2020_190801n701
Abstract: Apatinib (YN968D1) is a novel and highly selective tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2) and is approved as a third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction… read more here.
Keywords: adverse events; apatinib; management apatinib; events management ... See more keywords